Additional file 1 of A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau

Additional file 1: Fig. S1. Generation and genomic identification of hTau368 mice. Fig. S2. hTau368 had predominantly expression in hippocampus, slightly in other regions. Fig. S3. Reversible tau phosphorylation in hTau368 mice following dox-off. Fig. S4. Dox treatment increased hTau in the pan-cortex of hTau368 mice. Fig. S5. Dox-treated hTau368 mice showed enhanced Gallyas silver staining in DG granular cells, although the staining intensity was much slighter than that detected in the brain slice of AD patients. Fig. S6. Dox-treated hTau368 mice did not show amyloid deposition. Fig. S7. Dox treatment upregulated GSK-3β activity in the hippocampus of hTau368 mice. Fig. S8. Enhanced gliosis in entorhinal-piriform cortex of dox-treated hTau368 mice. Fig. S9. Dox treatment showed limited effect on glia activation in wild-type mice. Fig. S10. Reduction of tau correlates with increased synapse-associated proteins in hTau368 mice. Fig. S11. The loss of hippocampal neurons ceased when dox was retracted for hTau368 mice. Fig. S12. Dox-treated hTau368 mice tended to exhibit increased locomotor activities. Fig. S13. hTau368 mice showed no gender difference in tauopathy and cognitive behaviors. Table S1. Primers used for the identification of hTau368 mice. Table S2. Antibodies used in this study